Immunologic Response to FluMist vs. Flucelvax

PHASE4CompletedINTERVENTIONAL
Enrollment

465

Participants

Timeline

Start Date

September 20, 2019

Primary Completion Date

December 9, 2020

Study Completion Date

December 9, 2020

Conditions
Influenza, HumanImmune Response
Interventions
BIOLOGICAL

FluMist live attenuated influenza vaccine

Participants randomized to this study influenza vaccine arm will receive FluMist live attenuated influenza vaccine at baseline after the baseline blood draw is complete.

BIOLOGICAL

Flucelvax inactivated influenza vaccine

Participants randomized to this study influenza vaccine arm will receive Flucelvax cell-culture inactivated influenza vaccine at baseline after the baseline blood draw is complete.

Trial Locations (2)

15213

General Academic Pediatrics, Pittsburgh

15260

University of Pittsburgh Department of Family Medicine, Pittsburgh

All Listed Sponsors
collaborator

Centers for Disease Control and Prevention

FED

lead

Richard Zimmerman MD

OTHER

NCT03982069 - Immunologic Response to FluMist vs. Flucelvax | Biotech Hunter | Biotech Hunter